Cardio Diagnostics Holdings, Inc. CDIO
1.65 USD +0.04 (+2.81%)
At closeNov 4, 2026, 4:00 PM EST
1.65 0.00 +0.30%
After hours · Nov 4, 4:00 PM ET
1.60 Day range 1.69
0.97 52-week range 7.91
- YTD
- -39.30%
- 1 year
- -54.56%
- Market cap
- 4.87M
- Revenue (ttm)
- 39.14K
- EPS (ttm)
- -2.91
- Shares out
- 40.44M
- Forward P/E
- -4.12
- YTD return
- -39.30%
- 1-year return
- -54.56%
- Volume
- 9.09K
- Avg volume
- 35.69K
- Open
- 1.60
- Previous close
- 1.60
- Day's range
- 1.60 – 1.69
- 52-week range
- 0.97 – 7.91
- Beta
- 4.68
- Price target
- 2.00 (+21.6%)
- Earnings date
- Jul 1, 2024
5D -0.09 (-5.20%)
Key statistics
- Enterprise value
- 5.91M
- PEG ratio
- 0.00
- Price / sales
- 1064.26
- Price / book
- 7.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 356.20%
- Free cash flow
- -5.92M
- Total cash
- 1.31M
- Total debt
- 870.45K
- Return on equity
- -293.27%
- Short % of float
- 5.52%
- 50-day average
- 0.44336
- 200-day average
- 0.598455
Analyst view
Price target (mean) 2.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Jul 1, 2024
Expected Jul 1, 2024. Consensus EPS estimate -0.06.
Financials — quick view
CDIO Revenue — quarterly 5.36K
CDIO Net income — quarterly -1.50M
CDIO EPS — quarterly -0.51
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.15 | -0.06 | +0.09 | +60.00% |
| Jul 1, 2024 | Mar 1, 2024 | -0.10 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | -0.13 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Jun 6, 2024 | Benchmark | main | Speculative Buy | Speculative Buy |
| Apr 19, 2024 | Benchmark | main | Speculative Buy | Speculative Buy |
| Jun 15, 2023 | Benchmark | reit | Speculative Buy | Speculative Buy |
| May 22, 2023 | Northland Capital Markets | init | — | Outperform |
| Apr 18, 2023 | Benchmark | reit | — | Speculative Buy |
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cardiodiagnosticsinc.com
News
Critical Analysis: Genmab A/S (NASDAQ:GMAB) versus Cardio Diagnostics (NASDAQ:CDIO) 
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Shares Shorted: Short Interest Down 77.7% in September 
Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript 
Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head Analysis 
Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges 
Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges 
Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript 
Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City 
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026 
12 Health Care Stocks Moving In Friday's After-Market Session
Your note
Sign in to keep a note on CDIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURTON PAUL FREDERICK | Director | Conversion of Exercise of derivative security | Mar 27, 2024 | 8,803 |
| DOGAN MEESHANTHINI | Chief Technology Officer | Purchase | Sep 5, 2024 | 197,310 |
| DOGAN TIMUR | Chief Technology Officer | Purchase | Sep 5, 2024 | 197,310 |
| INTRATER JAMES | Director | Conversion of Exercise of derivative security | Mar 27, 2024 | 71,596 |
| LAU STANLEY K | Director | Conversion of Exercise of derivative security | Mar 27, 2024 | 100,325 |
| LEVY ODED | Director | Conversion of Exercise of derivative security | Mar 27, 2024 | 71,596 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.64% | 1,067,062 | 1.10M | Sep 29, 2024 |
| Vanguard Group Inc | 0.57% | 232,139 | 239.10K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.46% | 184,409 | 189.94K | Sep 29, 2024 |
| Northern Trust Corporation | 0.12% | 48,619 | 50.08K | Sep 29, 2024 |
| State Street Corporation | 0.11% | 43,500 | 44.80K | Sep 29, 2024 |
| PNC Financial Services Group, Inc. | 0.10% | 40,500 | 41.71K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.57% | 232,139 | 239.10K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.29% | 116,769 | 120.27K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 27,496 | 28.32K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 20,997 | 21.63K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 11,944 | 12.30K | Oct 30, 2024 |